Main public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

14:22, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Ubrogepant (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Ubrogepant |aOrAn=a |drugClass=Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist |indicationType=treatment |indication=migraine with or without aura in adults. |adverseReactions=Somnolence, Nausea, Dry mouth, Hypersensitivity reactions including rash, urticaria, and facial edema. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<span style="color...")
14:11, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Enhertu (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fam-trastuzumab deruxtecan-nxki |aOrAn=an |drugClass=Anti-HER2 antibody |indicationType=treatment |indication=Unresectable or metastatic HER2-positive and HER2-low breast cancer. Also for treating Unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) and Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. |hasBlackBoxWarning=Ye...")
13:35, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Lemborexant (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lemborexant |aOrAn=a |drugClass=Dual Orexin Receptor Antagonist (DORA) |indicationType=treatment |indication=adult patients with insomnia |adverseReactions=Somnolence, Fatigue, Headache, Abnormal dreams, Sleep paralysis, and Hypnagogic hallucinations. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
13:17, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Lumateperone tosylate (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lumateperone Tosylate |aOrAn=an |drugClass=Atypical Antipsychotic |indicationType=treatment |indication=schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥5% and twice the rate of placebo): somnolence/sedation, dry mouth. |blackBoxWarningTitle=Increased Mortalit...")
13:02, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Brilliant Blue G Ophthalmic Solution (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brilliant Blue G |aOrAn=a |drugClass=Disclosing Agent |indicationType=procedure |indication=staining the internal limiting membrane (ILM) during ophthalmic surgery. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult=Inject TissueBlue 0.025% directly into a Balanced Salt Solutio...")
12:51, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Padcev (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Enfortumab vedotin-ejfv |aOrAn=an |drugClass=Antineoplastic Agent |indicationType=treatment |indication=Locally advanced or metastatic urothelial cancer (mUC) in adult patients and Locally advanced or metastatic urothelial cancer (mUC) in adult patients who are ineligible for cisplatin-containing chemotherapy. |hasBlackBoxWarning=Yes |adverseReactions=Rash, alopecia, dry skin, pruritus, perip...")
12:29, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Golodirsen (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Golodirsen |aOrAn=an |drugClass=Antisense oligonucleotide |indicationType=treatment |indication=Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. |adverseReactions=Common Adverse Reactions (≥20% incidence): Headache, fever, fall, abdominal pain, nasopharyngitis, cough, vomiting, and nausea. |blackBoxWarningTitle=''...")
12:12, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Voxelotor (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Voxelotor |aOrAn=a |drugClass=Hemoglobin S polymerization inhibitor |indicationType=treatment |indication=sickle cell disease (SCD) in adults and pediatric patients aged 4 years and older. |adverseReactions=Common Adverse Reactions (≥10% incidence): Headache, diarrhea, abdominal pain, nausea, rash, and pyrexia. Note: As of September 2024, Pfizer has voluntarily withdrawn Oxbryta from al...")
11:51, 13 April 2025 Omid Afkhami-Ardakani talk contribs created page Cenobamate (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=cenobamate |aOrAn=a |drugClass=Sodium Channel Inhibitor |indicationType=treatment |indication=partial-onset seizures in adult patients. |adverseReactions=dizziness, somnolence, fatigue, headache, nausea, constipation, balance disorder, and rash. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content...")
15:15, 8 April 2025 Omid Afkhami-Ardakani talk contribs created page Givosiran (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Givosiran |aOrAn=a |drugClass=Small interfering RNA (siRNA) agent |indicationType=treatment |indication=acute hepatic porphyria (AHP) in adults. |adverseReactions=nausea, injection site reactions, fatigue, and elevated liver enzymes. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAd...")
14:29, 7 April 2025 Omid Afkhami-Ardakani talk contribs created page Adakveo (Created page with "{{DrugProjectFormSinglePage |genericName=Crizanlizumab-tmca |aOrAn=a |drugClass=Monoclonal Antibody |indicationType=prophylaxis |indication=vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. |adverseReactions=Nausea, Arthralgia (joint pain), Back pain, and Pyrexia (fever). |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition...")
12:41, 23 March 2025 Omid Afkhami-Ardakani talk contribs created page Cefiderocol (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid AfkhamiArdakani |genericName=Cefiderocol |aOrAn=a |drugClass=Siderophore Cephalosporin Antibiotic |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTIs), Hospital-Acquired Bacterial Pneumonia (HABP), and Ventilator-Associated Bacterial Pneumonia (VABP) in adult patients. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Infusion site reactions, Constipation, Rash, Candidiasis (including...")
00:47, 21 March 2025 Omid Afkhami-Ardakani talk contribs created page Zanubrutinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Zanubrutinib |aOrAn=a |drugClass=Bruton's Tyrosine Kinase (BTK) Inhibitor |indicationType=treatment |indication=Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Waldenström's Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and Follicular Lymphoma (FL) in adults. |adverseReactions=Decreased neutrophil count, Upper respiratory tract infection,...")
10:56, 20 March 2025 Omid Afkhami-Ardakani talk contribs created page Reblozyl (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Luspatercept-aamt |aOrAn=an |drugClass=Erythroid Maturation Agent |indicationType=treatment |indication=anemia in adult patients. More specifically anemia due to Beta Thalassemia, Myelodysplastic Syndromes (MDS), MDS with Ring Sideroblasts (MDS-RS) or Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). |adverseReactions=Fatigue, Headache, Musc...")
18:31, 17 March 2025 Omid Afkhami-Ardakani talk contribs created page Air polymer-type A (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Air polymer-type A intrauterine foam |aOrAn=an |drugClass=Ultrasound Contrast Agent |indication=sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility. |adverseReactions=Pelvic and abdominal pain, Nausea and faintness, Post-procedure spotting |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<span style="col...")
15:30, 17 March 2025 Omid Afkhami-Ardakani talk contribs created page Trikafta (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Elexacaftor, Tezacaftor, and Ivacaftor |aOrAn=a |drugClass=Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator |indicationType=treatment |indication=cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data. If the patient's genotype is unkn...")
14:58, 17 March 2025 Omid Afkhami-Ardakani talk contribs created page Fluorodopa F 18 (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fluorodopa F 18 |aOrAn=a |drugClass=Radiopharmaceutical Diagnostic Agent |indication=indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). |adverseReactions=Injection site pain |blackBoxWarningTitle='''TITLE''' |blackBoxWarn...")
10:35, 14 March 2025 Omid Afkhami-Ardakani talk contribs created page Brolucizumab–dbll (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brolucizumab-dbll |aOrAn=a |drugClass=Vascular Endothelial Growth Factor (VEGF) Inhibitor |indicationType=treatment |indication=Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |adverseReactions=Vision blurred, Cataract, Conjunctival hemorrhage, Eye pain, and Vitreous floaters. |blackBoxWarningTitle='''TITLE''' |blackBoxWa...")
22:01, 13 March 2025 Omid Afkhami-Ardakani talk contribs created page Trifarotene (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Trifarotene |aOrAn=a |drugClass=retinoid |indicationType=treatment |indication=acne vulgaris in patients 9 years of age and older |adverseReactions=Application site irritation, Application site pruritus (itching), Sunburn |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Trifarotene in adult patients. |offLabelAdultNoGuideSupport=There is lim...")
21:37, 12 March 2025 Omid Afkhami-Ardakani talk contribs created page Tenapanor (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Tenapanor |aOrAn=a |drugClass=Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor |indicationType=treatment |indication=irritable bowel syndrome with constipation (IBS-C) in adults. Also it v=can be used for reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea (16% in IBS-C patients; 43-53% in CKD patien...")
21:20, 12 March 2025 Omid Afkhami-Ardakani talk contribs created page Istradefylline (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=istradefylline |aOrAn=an |drugClass=Adenosine A₂A Receptor Antagonist |indicationType=treatment |indication=adult patients with Parkinson's disease (PD) experiencing "off" episodes along with treatment to levodopa/carbidopa |adverseReactions=Dyskinesia (involuntary muscle movements), Hallucinations Insomnia, Nausea, and Constipation. |offLabelAdultGuideSupport=There is limited information regard...")
21:19, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Ga-68-DOTATOC (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Gallium-68 DOTATOC |aOrAn=a |drugClass=radiopharmaceutical diagnostic agent |indicationType=procedure |indication=positron emission tomography (PET) imaging for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients. |adverseReactions=Nausea, Vomiting, Flushing, Injection site pain |blackBoxWarningTitle='''TITLE</...")
21:03, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Lefamulin (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lefamulin |aOrAn=a |drugClass=Pleuromutilin Antibiotic |indicationType=treatment |indication=adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. |adverseReactions=injection: administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, headache. Oral: diarrhea, nausea, vomiting, hepatic enzyme elevation. |blackBoxWarningTit...")
20:47, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Upadacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Upadacitinib |aOrAn=a |drugClass=Janus Kinase (JAK) Inhibitor |indicationType=treatment |indication=Moderate to severe active rheumatoid arthritis, Active psoriatic arthritis, Moderate to severe atopic dermatitis, Moderate to severe ulcerative colitis, Moderate to severe active Crohn's disease, Active ankylosing spondylitis, and Active non-radiographic axial spondyloarthritis. |hasBlackBoxWarning=Y...")
20:30, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Fedratinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Fedratinib |aOrAn=a |drugClass=Janus Kinase 2 (JAK2) Inhibitor |indicationType=treatment |indication=adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Nausea, Vomiting, Fatigue, Anemia, Thrombocytopenia, Elevated liver enzymes (ALT/AST), and Elevated...")
22:57, 8 February 2025 Omid Afkhami-Ardakani talk contribs created page Entrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Entrectinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. And also adult and pediatric patients 12 years of age and older with solid tumors. |adverseReactions=Fatigue, Constipation, Dysgeusia (altered taste), Edema, Dizziness, Diarrhea, Nausea, Dysesthesia (abnorma...")
13:14, 21 December 2024 Omid Afkhami-Ardakani talk contribs created page Pitolisant (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pitolisant |aOrAn=a |drugClass=Histamine-3 (H3) Receptor Antagonist/Inverse Agonist |indicationType=treatment |indication=Excessive daytime sleepiness (EDS) or cataplexy in adult patients and in pediatric patients aged 6 years and older with narcolepsy. |adverseReactions=Insomnia, Nausea, Anxiety, Headache, Irritability, Dizziness, Depression, Tremor, Sleep disorders, Fatigue, Vomiting, Vertigo, Dy...")
18:33, 8 December 2024 Omid Afkhami-Ardakani talk contribs created page Pretomanid (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pretomanid |aOrAn=a |drugClass=Nitroimidazooxazine Antimycobacterial |indicationType=treatment |indication=Pulmonary extensively drug-resistant (XDR) tuberculosis (TB), Treatment-intolerant or nonresponsive multidrug-resistant (MDR) pulmonary TB |adverseReactions=Peripheral neuropathy, Acne, Anemia, Nausea, Vomiting, Headache, Increased transaminases, Dyspepsia, Rash, and Decreased appetite. |fdaLI...")
17:55, 8 December 2024 Omid Afkhami-Ardakani talk contribs created page Pexidartinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pexidartinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Tenosynovial Giant Cell Tumor (TGCT). |hasBlackBoxWarning=Yes |adverseReactions=Increased liver enzymes (e.g., AST, ALT), Hair color changes, Increased cholesterol levels, Decreased white blood cell counts, Fatigue, Edema, Rash, and Dysgeusia (altered taste). Decreased phosphate levels |blackBoxWarning...")
17:03, 24 November 2024 Omid Afkhami-Ardakani talk contribs created page Nubeqa (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Darolutamide |aOrAn=a |drugClass=Nonsteroidal Antiandrogen (NSAA) |indicationType=treatment |indication=Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) in adult men. It can also be used for treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in combination with docetaxel in adult men. |adverseReactions=Fatigue, Pain in extremities, Rash, Decreased neutrophil count, and I...")
17:27, 17 November 2024 Omid Afkhami-Ardakani talk contribs created page Accrufer (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Ferric Maltol |aOrAn=an |drugClass=Oral Iron Replacement Therapy |indicationType=treatment |indication=iron deficiency in adults. |adverseReactions=Flatulence, diarrhea, constipation, discolored stools, abdominal pain, nausea, vomiting, and abdominal discomfort or bloating. |fdaLIADAdult=The recommended dosage is 30 mg orally twice daily, taken 1 hour before or 2 hours after a meal. |contraindicati...")
20:12, 2 November 2024 Omid Afkhami-Ardakani talk contribs created page Recarbrio (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Imipenem, Cilastatin, and Relebactam |aOrAn=an |drugClass=Antibacterial Combination |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), and Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) in patients 18 years and older. |adverseReactions=Nausea, Diarrhea, Headache, Fever, an...")
21:32, 25 October 2024 Omid Afkhami-Ardakani talk contribs created page Selinexor (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Selinexor |aOrAn=a |drugClass=Selective Inhibitor of Nuclear Export (SINE) |indicationType=treatment |indication=Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B-Cell Lymphoma (DLBCL) |hasBlackBoxWarning=Yes |adverseReactions=Nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, weight loss |blackBoxWarningTitle=Serious Hematologic a...")
16:41, 16 October 2024 Omid Afkhami-Ardakani talk contribs created page Vyleesi (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Vyleesi |aOrAn=a |drugClass=Melanocortin receptor agonist |indicationType=treatment |indication=hypoactive sexual desire disorder (HSDD) in premenopausal women |adverseReactions=nausea (40%), flushing (20%), injection site reactions (13%), headache (11%), and vomiting (4.8%) |fdaLIADAdult=Vyleesi is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre...")
15:02, 19 September 2024 Omid Afkhami-Ardakani talk contribs created page Polivy (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Polivy |aOrAn=a |drugClass=HUMAN PRESCRIPTION DRUG LABEL |indicationType=treatment |indication=POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: 1. in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise speci...")

Main public logs

Navigation menu

Search